Top

Published in:

01-07-2007 | Oncology

The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients

Authors: Martijn R. Meijerink, Hester van Cruijsen, Klaas Hoekman, Matthijs Kater, Cors van Schaik, Jan Hein T. M. van Waesberghe, Giuseppe Giaccone, Radu A. Manoliu

Published in: European Radiology | Issue 7/2007

Abstract

The purpose of this study was to determine the feasibility of dynamic contrast–enhanced perfusion CT (CTP) in evaluating the hemodynamic response of tumors in the chest and abdomen treated with a combination of AZD2171 and gefitinib. Thirteen patients were examined just before and every 4-6 weeks after starting therapy. Following intravenous injection of a contrast agent, dynamic image acquisition was obtained at the level of a selected tumor location. To calculate perfusion, the maximum-slope method was used. Pre-treatment average perfusion for extra-hepatic masses was 84 ml/min/100 g, for liver masses arterial perfusion was 25 ml/min/100 g, and a portal perfusion of 30 ml/min/100 g was found. After the administration of AZD2171 and gefitinib, in extra-hepatic masses an initial decrease in perfusion of 18% was followed by a plateau and in liver masses an initial decrease of 39% within the lesions and of 36% within a rim region surrounding the lesions was followed by a tendency to recovery of hepatic artery flow. In conclusion, CTP is feasible in showing changes of perfusion induced by anti-angiogenic therapy.

Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186PubMedCrossRef

World Health Organisation (1979) WHO Handbook for reporting results of cancer treatment. World Health Organisation, Geneva, Switzerland, p 48

Hawthorn J (1994) A practical guide to EORTC studies. European Organisation for the Research and Treatment of Cancer (EORTC), Brussels

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer 92:205–216CrossRef

Miles KA, Hayball M, Dixon AK (1991) Colour perfusion imaging: a new application of computed tomography. Lancet 337:643–645PubMedCrossRef

Miles KA (1991) Measurement of tissue perfusion by dynamic computed tomography. Br J Radiol 64:409–412PubMedCrossRef

Swensen SJ, Viggiano RW, Midthun DE, Muller NL, Sherrick A, Yamashita K, Naidich DP, Patz EF, Hartman TE, Muhm JR, Weaver AL (2000) Lung nodule enhancement at CT: multicenter study. Radiology 214:73–80PubMed

Zhang M, Kono M (1997) Solitary pulmonary nodules: evaluation of blood flow patterns with dynamic CT. Radiology 205:471–478PubMed

Leggett DA, Kelley BB, Bunce IH, Miles KA (1997) Colorectal cancer: diagnostic potential of CT measurements of hepatic perfusion and implications for contrast enhancement protocols. Radiology 205:716–720PubMed

10.

Dugdale PE, Miles KA, Bunce I, Kelley BB, Leggett DA (1999) CT measurements of perfusion and permeability within lymphoma masses and its ability to assess grade, activity and chemotherapeutic response. J Compu Assist Tomogr 23:540–547CrossRef

11.

Miles KA, Leggett DAC, Kelley BB, Hayball MP, Sinnatamby R, Bunce I (1998) In vivo assessment of neovascularization of liver metastases using perfusion CT. Br J Radiol 71:276–281PubMed

12.

Hermans R, Meijerink M, Van den Bogaert W, Rijnders A, Weltens C, Lambin P (2003) Tumor perfusion rate determined noninvasively by dynamic computed tomography predicts outcome in head-and-neck cancer after radiotherapy. Int J Radiat Oncol Biol Phys 57:1351–1356PubMedCrossRef

13.

Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145–147PubMedCrossRef

14.

Xiong HQ, Herbst R, Faria SC, Scholz C, Davis D, Jackson EF, Madden T, McConkey D, Hicks M, Hess K, Charnsangavej C, Abbruzzese JL (2004) A phase I surrogate endpoint study of SU6668 in patients with solid tumors. Invest New Drugs 22:459–466PubMedCrossRef

15.

Thomas JP, Arzoomanian RZ, Alberti D, Marnocha R, Lee F, Friedl A, Tutsch K, Dresen A, Geiger P, Pluda J, Fogler W, Schiller JH, Wilding G (2003) Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 21:223–231PubMedCrossRef

16.

Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, Chester R, Jackson JA, Boffey SJ, Kilburn LL, Barnett S, Richmond GH, Wadsworth PF, Walker M, Bigley AL, Taylor ST, Cooper L, Beck S, Jurgensmeier JM, Ogilvie DJ (2005) AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65:4389–4400PubMedCrossRef

17.

Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 21:2237–2246PubMedCrossRef

18.

Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290:2149–2158PubMedCrossRef

19.

Wedge SR, Kendrew J, Hennequin LF (2005) AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65:4389–4400PubMedCrossRef

20.

Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655PubMed

21.

Tsushima Y, Funabasama S, Aoki J, Sanada S, Endo K (2004) Quantitative perfusion map of malignant liver tumors, created from dynamic computed tomography data. Acad Radiol 11:215–223PubMedCrossRef

22.

Tsushima Y, Funabasama S, Sanada S, Aoki J, Endo K (2002) Development of perfusion CT software for personal computers. Acad Radiol 9:922–926PubMedCrossRef

23.

Miles KA, Hayball MP, Dixon AK (1993) Functional images of hepatic perfusion obtained with dynamic CT. Radiology 188:405–411PubMed

24.

Tsushima Y, Blomley MJ, Kusano S, Endo K (2002) Measuring portal venous perfusion with contrast-enhanced CT: comparison of direct and indirect methods. Acad Radiol 9:276–282PubMedCrossRef

25.

Mullani N, Herbst R, Abbruzzese J, Charnsangavej C, Kim E, Tran H, Barron B, Lamki L, Gould K (2000) Antiangiogenic treatment with endostatin results in uncoupling of blood flow and glucose metabolism in human tumors. Clin Positron Imaging 3:151CrossRefPubMed

26.

Maxwell RJ, Wilson J, Prise VE, Vojnovic B, Rustin GJ, Lodge MA, Tozer GM (2002) Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI. NMR Biomed 15:89–98PubMedCrossRef

27.

Thomas AL, Morgan B, Horsfield MA, Higginson A, Kay A, Lee L, Masson E, Puccio-Pick M, Laurent D, Steward WP (2005) Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 23:4162–4171PubMedCrossRef

28.

Miller KD, Miller M, Mehrotra S, Agarwal B, Mock BH, Zheng QH, Badve S, Hutchins GD, Sledge GW Jr (2006) A physiologic imaging pilot study of breast cancer treated with AZD2171. Clin Cancer Res 12:281–288PubMedCrossRef

29.

Tsushima Y, Blomley MJ, Yokoyama H, Kusano S, Endo K (2001) Does the presence of distant and local malignancy alter parenchymal perfusion in apparently disease-free areas of the liver? Dig Dis Sci 46:2113–2119PubMedCrossRef

30.

van Cruijsen H, Voest EE, van Herpen CM, Hoekman K, Witteveen PO, Punt CJ, Puchalski TA, Fernandes N, Koehler M, Giaccone G (2005) Phase I evaluation of AZD2171 in combination with gefinitib (Iressa) in patients with advanced tumours. Proc Am Soc Clin Oncol Abstract 3030

31.

Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, Jayson GC, Judson IR, Knopp MV, Maxwell RJ, McIntyre D, Padhani AR, Price P, Rathbone R, Rustin GJ, Tofts PS, Tozer GM, Vennart W, Waterton JC, Williams SR, Workman P; Pharmacodynamic/Pharmacokinetic Technologies Advisory Committee, Drug Development Office, Cancer Research UK (2005) The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 92:1599–1610PubMedCrossRef

32.

Ridge JA, Bading JR, Gelbard AS, Benua RS, Daly JM (1987) Perfusion of colorectal hepatic metastases. Relative distribution of flow from the hepatic artery and portal vein. Cancer 59:1547–1553PubMedCrossRef

33.

Kruskal JB, Thomas P, Kane RA, Goldberg SN (2004) Hepatic perfusion changes in mice livers with developing colorectal cancer metastases. Radiology 231:482–490PubMedCrossRef

34.

Miles KA, Leggett DA, Kelley BB, Hayball MP, Sinnatamby R, Bunce I (1998) In vivo assessment of neovascularization of liver metastases using perfusion CT. Br J Radiol 71:276–281PubMed

35.

Irie T, Tsushima Y, Terahata S, Hatsuse K, Kusano S, Itai Y (1997) Rim enhancement in colorectal metastases at CT during infusion hepatic arteriography. Does it represent liver parenchyma or live tumor cell zone? Acta Radiol 38:416–421PubMed

36.

Blomley MJ, Coulden R, Dawson P, Kormano M, Donlan P, Bufkin C, Lipton MJ (1995) Liver perfusion studied with ultrafast CT. J Comput Assist Tomogr 19:424–433PubMedCrossRef

37.

Tsushima Y, Blomley MJ, Kusano S, Endo K (1999) The portal component of hepatic perfusion measured by dynamic CT: an indicator of hepatic parenchymal damage. Dig Dis Sci 44:1632–1638PubMedCrossRef

38.

Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58–62PubMedCrossRef

39.

Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, Munn LL, Jain RK (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6:553–563PubMed

40.

Brix G, Bahner ML, Hoffmann U, Horvath A, Schreiber W (1999) Regional blood flow, capillary permeability, and compartmental volumes: measurement with dynamic CT-initial experience. Radiology 210:269–276PubMed

41.

Pandharipande PV, Krinsky GA, Rusinek H, Lee VS (2005) Perfusion imaging of the liver: current challenges and future goals. Radiology 234:661–673PubMedCrossRef

42.

Leveson SH, Wiggins PA, Nasiru TA, Giles GR, Robinson PJ, Parkin A (1983) Improving the detection of hepatic metastases by the use of dynamic flow scintigraphy. Br J Cancer 47:719–721PubMed

43.

Krix M, Plathow C, Kiessling F, Herth F, Karcher A, Essig M, Schmitteckert H, Kauczor HU, Delorme S (2004) Quantification of perfusion of liver tissue and metastases using a multivessel model for replenishment kinetics of ultrasound contrast agents. Ultrasound Med Biol 30:1355–1363PubMedCrossRef

44.

Harpen MD, Lecklitner ML (1984) Derivation of gamma variate indicator dilution function from simple convective dispersion model of blood flow. Med Phys 11:690–692PubMedCrossRef

45.

Materne R, Smith AM, Peeters F, Dehoux JP, Keyeux A, Horsmans Y, Van Beers BE (2002) Assessment of hepatic perfusion parameters with dynamic MRI. Magn Reson Med 47:135–142PubMedCrossRef

46.

Jackson A, Haroon H, Zhu XP, Li KL, Thacker NA, Jayson G (2002) Breath-hold perfusion and permeability mapping of hepatic malignancies using magnetic resonance imaging and a first-pass leakage profile model. NMR Biomed 15:164–173PubMedCrossRef

47.

Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, Port RE, Taylor J, Weisskoff RM (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10:223–232PubMedCrossRef

48.

Padhani AR, Hayes C, Landau S, Leach MO (2002) Reproducibility of quantitative dynamic MRI of normal human tissues. NMR Biomed 15:143–153PubMedCrossRef

49.

Van Beers BE, Leconte I, Materne R, Smith AM, Jamart J, Horsmans Y (2001) Hepatic perfusion parameters in chronic liver disease: dynamic CT measurements correlated with disease severity. Am J Roentgenol 176:667–673

50.

Turetschek K, Floyd E, Helbich T, Roberts TP, Shames DM, Wendland MF, Carter WO, Brasch RC (2001) MRI assessment of microvascular characteristics in experimental breast tumors using a new blood pool contrast agent (MS-325) with correlations to histopathology. J Magn Reson Imaging 14:237–242PubMedCrossRef

51.

Fournier LS, Cuenod CA, de Bazelaire C, Siauve N, Rosty C, Tran PL, Frija G, Clement O (2004) Early modifications of hepatic perfusion measured by functional CT in a rat model of hepatocellular carcinoma using a blood pool contrast agent. Eur Radiol 14:2125–2133PubMedCrossRef

52.

Kety SS (1951) The theory and applications of the exchange of inert gas at the lungs and tissues. Pharmacol Rev 3:1–41PubMed

53.

Kety SS (1960) Theory of blood-tissue exchange and its application to measurement of blood flow. Methods Med Res 8:228–236

54.

Wells P, Jones T, Price P (2003) Assessment of inter- and intra-patient variability in C15O2 positron emission tomography measurements of blood flow in patients with intra-abdominal cancers. Clin Cancer Res 9:6350–6356PubMed

55.

Flower MA, Zweit J, Hall AD, Burke D, Davies MM, Dworkin MJ, Young HE, Mundy J, Ott RJ, McCready VR, Carnochan P, Allen-Mersh TG (2001) 62Cu-PTSM and PET used for the assessment of angiotensin II-induced blood flow changes in patients with colorectal liver metastases. Eur J Nucl Med 28:99–103PubMedCrossRef

56.

Miller JC, Pien HH, Sahani D, Sorensen AG, Thrall JH (2005) Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst 97:172–187PubMedCrossRef

57.

Materne R, Van Beers BE, Smith AM, Leconte I, Jamart J, Dehoux JP, Keyeux A, Horsmans Y (2000) Non-invasive quantification of liver perfusion with dynamic computed tomography and a dual-input one-compartmental model. Clin Sci (Lond) 99:517–525CrossRef

58.

Axel L (1980) Cerebral blood flow determination by rapid-sequence computed tomography: theoretical analysis. Radiology 137:679–686PubMed

59.

Gobbel GT, Cann CE, Fike JR (1991) Measurement of regional cerebral blood flow using ultrafast computed tomography. Theoretical aspects. Stroke 22:768–771PubMed

60.

Nabavi DG, Cenic A, Craen RA, Gelb AW, Bennett JD, Kozak R, Lee TY (1999) CT assessment of cerebral perfusion: experimental validation and initial clinical experience. Radiology 213:141–149PubMed

61.

Cenic A, Nabavi DG, Craen RA, Gelb AW, Lee TY (2000) A CT method to measure hemodynamics in brain tumors: validation and application of cerebral blood flow maps. Am J Neuroradiol 21:462–470PubMed

62.

Kiessling F, Boese J, Corvinus C, Ederle JR, Zuna I, Schoenberg SO, Brix G, Schmahl A, Tuengerthal S, Herth F, Kauczor HU, Essig M (2004) Perfusion CT in patients with advanced bronchial carcinomas: a novel chance for characterization and treatment monitoring? Eur Radiol 14:1226–1233PubMed

63.

Mullani NA, Gould KL (1983) First-pass measurements of regional blood flow with external detectors. J Nucl Med 24:577–581PubMed

64.

Gillard JH, Antoun NM, Burnet NG, Pickard JD (2001) Reproducibility of quantitative CT perfusion imaging. Br J Radiol 74:552–555PubMed

65.

Blomley MJ, Kormano M, Coulden R, Lim-Dunham J, Dawson P, Lipton MJ (1997) Splenic blood flow: evaluation with computed tomography. Acad Radiol 4:13–20PubMedCrossRef

66.

ICRP Publication 60 (1991) 1990 Recommendations of the International Commission on Radiological Protection. Ann ICRP 31:1–3

Title: The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients
Authors: Martijn R. Meijerink
Hester van Cruijsen
Klaas Hoekman
Matthijs Kater
Cors van Schaik
Jan Hein T. M. van Waesberghe
Giuseppe Giaccone
Radu A. Manoliu
Publication date: 01-07-2007
Publisher: Springer-Verlag
Published in: European Radiology / Issue 7/2007
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-006-0425-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2007

Thioguanin-induced nodular regenerative hyperplasia of the liver-ROC analysis of different MR techniques

Early mammographic and sonographic findings after intraoperative radiotherapy (IORT) as a boost in patients with breast cancer

Unexpected finding of elevated glucose uptake in fibrous dysplasia mimicking malignancy: contradicting metabolism and morphology in combined PET/CT

Silicone-selective multishot echo-planar imaging for rapid MRI survey of breast implants

Significance of mesorectal volume in staging of rectal cancer with magnetic resonance imaging and the assessment of involvement of the mesorectal fascia

Cartilage lesions of the glenohumeral joint: diagnostic effectiveness of multidetector spiral CT arthrography and comparison with arthroscopy